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Abstract 
A quantitative TLC method was developed for the simultaneous separation and 
quantification of glimepiride and its main degradation impurities, glimepiride-
sulfonamide and glimepiride-carbamate. Chromatographic analysis was performed using 
the commercial aluminium-backed TLC plates precoated with silica gel 60F254 as 
stationary phase, and toluene-ethyl acetate–methanol 8:5:1 (v/v) as mobile phase. 
Detection was performed at 230 nm. Regression coefficients (r> 0.997), recovery (94.9 to 
105.1 %), determination limit of impurities (7 ng spot-1 equivalent to the 0.1% impurity 
level), and robustness were validated and found to be satisfactory. The method is 
convenient for quantitative analysis and purity control of glimepiride in its dosage forms.  
 
KEYWORDS: TLC, glimepiride, impurities, quantification, pharmaceutical dosage 
forms 
 
INTRODUCTION 
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Glimepiride  is an orally active hypoglycemic drug belonging to the sulfonylurea group 
and it can be used in the non-insulin dependent diabetes mellitus cases. It is classified as 
a second-generation antidiabetic drug[1] and – like the other drugs belonging to this group 
– it shows an increased potency, a more rapid onset, a shorter plasma half-live, and a 
longer duration of action. 
 
The presence of the sulfonylurea bridge, a carboxamide linkage, a constrained lactam 
ring, and an α,β-unsaturated carbonyl system make glimepiride susceptible to 
degradation as a result of the lability of these linkages and functional groups to hydrolysis 
and photolysis[2]. As a result, several degradation products are assumed to be formed in 
the course of the formal stability testing of the drug. The presence of impurities can have 
a significant impact on the quality and safety of the glimepiride dosage products. 
 
A recently published review paper devoted to the different analytical techniques for 
qualitative and quantitative determination of glimepiride in biological samples and 
pharmaceutical formulations has covered information contained in 55 references[3]. With 
respect of the pronounced labile of glimepiride, several high performance liquid 
chromatographic (HPLC) methods were developed for the separation of glimepiride and 
its impurities originating from the synthesis (as process impurities), or appearing as the 
degradation products, mostly from API (active pharmaceutical ingredients)[2,4,5], or the 
pharmaceutical drug products[6,7]. The drug substance monograph of glimepiride in 
European Pharmacopoeia (EP) lists ten impurities (A-J)[8], while the United States 
Pharmacopeia (USP) lists three impurities, glimepiride-sulfonamide, glimepiride-
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urethane (carbamate), and glimepiride-3-isomer[9]. According to USP and the 
requirements for dosage formulations (tablets), such degradants as glimepiride-
sulfonamide, are required to be quantitatively tested. Besides glimepiride-sulfonamide, 
certain manufacturers require quantitative testing of glimepiride-carbamide in the final 
dosage form. These two degradants were suggested to be formed due to the hydrolysis of 
the sulfonylurea bridge. The chemical structures of glimepiride, glimepiride-sulfonamide, 
and glimepiride-carbamate are given in Fig. 1. 
 
TLC has been used for the determination of the multi-component dosage formulations 
containing glimepiride in the presence of pioglitazone[10,11], pioglitazone and 
metformin[12], and metformin and atorvastatin[13]. HPLC and TLC have been used for the 
determination of glimepiride and pioglitazone in pharmaceutical formulations[14]. So far, 
no reports are available on the thin-layer chromatographic methods for the determination 
of glimepiride and its main degradation impurities. 
 
In this paper, we present a simple, rapid, accurate, and precise thin-layer chromatographic 
method for a simultaneous determination of glimepiride and its main degradation 
products (glimepiride-sulfonamide and glimepiride-carbamate), which need to be 
monitored in the pharmaceutical dosage forms, according to certain manufacturers, or to 
the pharmacopoeia requirements. 
 
EXPERIMENTAL  
Materials 
D
ow
nl
oa
de
d 
by
 [D
an
ica
 A
gb
ab
a] 
at 
02
:20
 10
 A
pr
il 2
01
3 
ACCEPTED MANUSCRIPT 
ACCEPTED MANUSCRIPT 
4
1-[[4-[2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)-ethyl]phenyl]sulphonyl]-
3-trans- (4-methylcyclohexyl)urea (glimepiride), 3-ethyl- 4-methyl-2-oxo-N – [2-(4-
sulfamoylphenyl) ethyl]-2,3-dihydro-1H-pyrrole-1-carboxamide (glimepiride-
sulfonamide), and methyl [4-[2-(3-ethyl-4-methyl-2-oxo-2,3-didydro-1H- pyrrol-1-
yl)carbonyl] ethyl] phenyl]sulfonyl]carbamate (glimepiride-carbamate), were kindly 
donated by Sanofi-Aventis, Scoppito (Italy). Amaryl 3 mg tablets (Sanofi-Aventis, 
Scoppito, Italy), Limeral 4 mg tablets (Zdravlje-Actavis Company, Leskovac, Serbia), 
and Dibiglim 3 mg  tablets (Sandoz Pharmaceuticals, Lubljana, Slovenia) were also used 
in our study. 
 
Solutions 
Standard Solutions 
Stock solution of glimepiride as the standard substance (0.3 mg mL-1) and stock solutions 
of the impurities, glimepiride-sulfonamide and glimepiride-carbamate (0.1 mg mL-1), 
were prepared in methanol. 
 
Five glimepiride calibration solutions containing 0.120-0.180 mg mL-1 of the test 
compound were prepared by diluting the stock solution. The 1-µL aliquot of each 
glimepiride calibration solution was applied to the chromatographic plate. Five 
calibration solutions containing the impurities were prepared by diluting the stock 
solutions to obtain the solutions containing 0.002 – 0.02 mg mL-1 of glimepiride-
sulfonamide and glimepiride-carbamate. The 5-µL aliquots of each glimepiride-
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sulfonamide and glimepiride-carbamate calibration solution were applied to the 
chromatographic plates. 
 
Sample Solutions 
Ten tablets of each sample were weighed and pulverized. The quantity of the powdered 
tablets containing 1.5 mg glimepiride was transferred to the 10-mL volumetric flask and 
dissolved in 5 mL methanol, using an ultrasonic bath for 5 min. The solutions were then 
diluted to the volume with the same solvent and filtered through the 0.45-µm pore size 
membrane filter (Millipore). For the assay of glimepiride, the 1-µL aliquot of the filtrate 
was applied to the plate. 
 
The quantity of the powdered tablets containing 3 mg glimepiride was transferred to the 
5-mL volumetric flask and dissolved in 3 mL methanol, using an ultrasonic bath for 5 
min. The solution was than diluted to the volume with the same solvent and filtered 
through the 0.45-µm pore size membrane filter (Millipore). For the assay of the 
impurities, the 10-µL aliquots of the filtrates were applied to the plate. 
 
Chromatography 
Chromatography was performed on the 20 cm × 10 cm thin-layer chromatographic plates 
cut from the 20 cm × 20 cm aluminium plates, precoated with silica gel 60 F254 (Merck, 
Darmstadt, Germany). Standard and sample solutions were applied 15 mm above the 
lower edge of the plate, using a Camag (Muttenz, Switzerland) Nanomat II application 
device. Ascending chromatography to a distance of 80 mm was performed in the twin-
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trough TLC chamber, previously saturated for 20 min . The mobile phases was toluene-
ethyl acetate–methanol, 8:5:1 (v/v). After the development, the plates were dried in 
ambient air and the separated zones were scanned in the linear reflectance–absorbance 
mode at 230 nm by means of a Camag TLC Scanner II with a computer system and Cats 
software (V.3.15). The peak areas were used for quantification.  
 
RESULTS AND DISCUSSION 
Optimization of working conditions for a simple, rapid and reproducible analysis usually 
involves selection of appropriate stationary or mobile phases. In our case, in order to 
obtain a satisfactory resolution and to avoid peak tailing, optimization was performed 
with different mobile phase. The retention behavior using single non polar (toluene, 
cyclohexane) and polar (methanol, acetonitrile) solvents was investigated. 
 
In a non polar solvent (e.g., toluene), all investigated substances were retained on the start 
line. In the binary system (toluene-ethyl acetate, 1:1 (v/)), a diffused and largely retained 
zone with poor resolution was observed close to the start line. Polar solvents were 
apparently needed to suppress strong intermolecular interactions between the polar 
groups of the investigated impurities and the silanol groups of silica gel. A satisfactory 
resolution and separation of glimepiride and its impurities (glimepiride-sulfonamid and 
glimepiride-carbamate) was obtained using methanol as a modifier. The best resolution 
was obtained with toluene-ethyl acetate–methanol, 8:5:1 (v/v). Using the same solvent 
system, no better separation, or better peak response was achieved on the HPTLC, or 
HPTLC LiCrospher Si 60 plates, or on the modified silica reverse phase stationary phase. 
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Hence, the less expensive TLC plates were used for further validation of the elaborated 
thin-layer chromatographic method. 
 
The migration distances of glimepiride, glimepiride-sulfonamide, and glimepiride-
carbamate were 48.4 mm, 43.0 mm, and 34.5 mm, respectively. The absorption UV 
spectra of all three substances were recorded and the optimum wavelength for the 
densitometric assessment was chosen as equal to 230 nm. The relationships between the 
peak areas and the amounts of the substances applied were evaluated with use of the 
linear and the second degree polynomial regression functions. For glimepiride, linear 
regression was proved as performing well enough, because of the narrower range of the 
concentrations tested. For the two impurities, i.e., glimepiride-sufonamide and 
glimepiride-carbamate, the second-degree polynomial function was employed, because a 
wider range of concentrations was required for quantitation of the impurities in the 
method of purity assessment. The regression parameters are summarized in Table 1. 
 
An effect of larger amounts of the drug on the peak shape and the resolution of the 
impurities had to be determined, in order to avoid systematic errors. An accuracy of the 
method was therefore proved by determination of the impurities (i.e., glimepiride-
sulfonamide and glimepiride-carbamate) in the presence of glimepiride. The tablet matrix 
(i.e., a mixture of the excipients) was spiked with 0.6 mg mL-1 glimepiride, and with 0.02 
mg mL-1, 0.005 mg mL-1,  and 0.002 mg mL-1 glimepiride-sulfonamide and glimepiride-
carbamate, respectively (corresponding to 0.3-3.0%, respectively) . The densitometrically 
scanned concentration profiles obtained from the spiked samples of glimepiride are 
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presented in Fig. 2. The calculated recoveries (the corresponding standards without 
glimepiride) were plotted against the expected values. The recoveries and the relative 
standard deviations (RSD) for glimepiride-sulfonamide and glimepiride-carbamate were 
acceptable for the method of purity assessment (Table 2). The recovery of glimepiride 
from a laboratory-prepared mixture of the excipients spiked with the three different 
concentrations (0.18 mg mL-1, 0.15 mg mL-1 and 0.12 mg mL-1) is given also in Table 2. 
The recovery of glimepiride ranging from 98.9 to 102.1%, and the RSD values lower 
than 2% confirms the accuracy of the method. 
 
The repeatability of the method was assessed the by replicate chromatography 
applications (n=6) of glimepiride and the impurities (i.e., glimepiride-sulfonamide and 
glimepiride-carbamate) at the three different concentrations. The statistical data (i.e., the 
RSD values) obtained from these results are listed in Table 3. 
 
The limit of detection (LOD) and the limit of quantification (LOQ) were determined by 
fitting the back-calculated inter-day standard deviation for each calibration standard. The 
y-intercept was then equal to SD0 (the estimated standard deviation at the zero 
concentration). According to the defined LOD and LOQ values (3SD0 and 10SD0, 
respectively), the sample amount applied to the plate at which it can be detected or 
quantified was established. The LOD values for the impurities (i.e., glimepiride-
sulfonamide and glimepiride-carbamate) were found as equal to 2.19 and 2.30 ng spot-1, 
respectively (which is equivalent to the percent level of 0.04% for both impurities). The 
LOQ values for the impurities (i.e., glimepiride-sulfonamide and glimepiride-carbamate) 
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were found as equal to 7.24 and 7.69 ng spot-1 (which is equivalent to the percent level of 
0.1% for both impurities). 
 
Robustness is the measure of the capacity of the method to remain unaffected by small 
but deliberate variation of the method conditions, and it is an indication of the reliability 
of the method [15,16]. Since planar chromatography is an open chromatographic method, 
the environmental conditions can significantly influence its results. Thus, the temperature 
was chosen as one of the critical factors to be tested. Variation of the temperature 
between 15 and 25oC exerts no observable effect on the separation of glimepiride and its 
impurities. Apart from the temperature changes, we also examined the influence of the 
contents of all three solvents, i.e., methanol, toluene, and ethyl acetate, in mobile phase. 
These contents varied in the ±10% range and no observable effect on the separation and 
resolution among the peaks was perceived. The geometry of the twin-trough chamber and 
the flat-bottom chamber can influence (i.e., differentiate) the retention of the investigated 
compounds. The use of the twin-trough chamber was found as preferable for quantitative 
evaluation of glimepiride and its impurities.  
 
The method was used to screen the commercial glimepiride tablets. The results are 
presented in Table 4. Compared with the label declaration, the recoveries of glimepiride 
from the dosage forms were very high. The RSD values obtained for the tablets (1.8 – 2.5 
%) confirm the accuracy of the method. The impurity levels for glimepiride-sulfonamide 
(0.21 – 0.31 %) did not exceed the requirement for its limit, neither according to the 
different manufacturers of the generic glimepiride tablets (0.8-2%), nor according to USP 
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(2.5%). The low LOQ value of the proposed thin-layer chromatographic method for both 
impurities enables testing of these two compounds in the glimepiride drug substances 
according to the pharmacopoeial requirements, not exceeded 0.4%. 
 
CONCLUSION 
The obtained results suggest that TLC is an efficient method for the separation and 
quantitative determination of glimepiride and its main degradation products. This simple 
and economical method is suitable for the separation and quantitative determination of 
the purity of glimepiride in its dosage forms. It can therefore be used for the routine 
quality control and performance of the formal stability study of glimepiride in its dosage 
forms.  
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Table 1. Statistical Data for the Calibration Curves 
Substance n ng spot-1 Calibration function y=a +bx SD R 
a     b 
Glimepiride  5 180-120 -276.276 5.2014 12.76 0.997
   Calibration function y=a +bx+cx2   
   a    b     c 
Glimepiride-sulfonamide 5 100-10 5.534 10.442 -0.028 7.68 0.999
Glimepiride-carbamate 5 100-10 10.870 7.41 -0.000708 5.7 0.998
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Table 2. Accuracy of Method Expressed as a Recovery of the Analyte Spiked to the 
Placebo Mixture 
Compound Spiked ng 
spot-1 
Found ng spot-1 Recovery (%) RSD 
(%) 
Glimepiride 180 183.85 102.1 1.55 
 150 150.36 100.2 1.15 
 120 118.75 98.9 1.21 
Glimepiride-sulfonamide 100 94.88 94.9 3.85 
 25 26.27 105.1 2.64 
 10 10.17 101.7 3.80 
Glimepiride-carbamate 100 96.74 96.7 3.50 
 25 25.37 101.5 3.35 
 10 10.23 102.3 5.17 
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Table 3. Precision of the Method  
Amount ng spot-1 Glimepiride 
RSD (%) 
Glimepiride-sulfonamide 
RSD (%) 
Glimepiride-carbamate 
RSD (%) 
180 0.9   
150 1.2   
130 1.8   
100  1.7 3.8 
25  2.7 2.7 
10  3.9 4.2 
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Table 4. Results of TLC Determination of Glimepiride and Its Impurities 
Sample Glimepiride 
(mg ±RSD) 
Glimepiride-
sulfonamide (% ±RSD) 
Glimepiride-carbamate 
(% ±RSD) 
Amaryl  3 mg 2.95±1.83 0.21±5.4 - 
Limeral  4 mg 4.05±2.47 0.31±4.4 - 
Dibiglim 3 mg   2.85±2.23 0.29±4.8 - 
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Figure 1. Chemical structures of glimepiride, glimepiride-sulfonamide, and glimepiride-
carbamate. 
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Figure 2. Densitograms obtained for: (a,c) 25 ng and 10 ng mixture of each standard, 
respectively; glimepiride-carbamate (peak 1) and glimepiride-sulfonamide (peak 2); (b,d) 
samples of glimepiride (peak 3) spiked with 0.8 and 0.3%, respectively, of the impurities 
glimepiride-carbamate and glimepiride-sulfonamide; (e) sample of the glimepiride tablet. 
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